Related Experiment Videos
Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS)
Abstract:
The ability of trinitrophenylated tumor cells to stimulate syngeneic antitumor response has been tested in 3 different tumor-host systems: A. Trinitrophenylated and inactivated Moloney induced YAC tumor cells (YAC-TNP) were able to induce the production of cytotoxic antibodies in low responding A/J mice, while inactivated YAC tumor cells (YAC-In) failed to induce such a response. Furthermore, A mice which were injected with YAC-TNP rejected 103 viable YAC tumor cells at a higher frequency than those injected with YAC-In. B. Trinitrophenylated and inactivated Gross virus induced G-35 tumor cells or Monoloney induced LSTRA cells (both syngeneic in BALB/c mice) were as immunogenic as nonmodified inactivated tumor cells. About 50% of the immunized mice survived indefinitely after injection of 103 viable tumors. Fruthermore, spleen cells from mice primed with either modified or nonomodified G-35 cells responded in vitro to G-35 in a mixed leukocyte tumor interaction and generated specific cell-mediated cytotoxic activity to 51Cr-G-35 syngeneic tumors. However, the donors of the primed cells did not produce detectable cytotoxic antibodies to G-35. C. In vitro sensitization of C57B1 spleen cells by trinitrophenylated Mitomycin C treated syngeneic EL-4 generated a stronger cytotoxic response to EL-4 cells than obtained by sensitization with Mitomycin C treated EL-4 cells alone, The superiority of the sensitizing capacity of trinitrophenylated EL-4 was readily demonstrated in conditions which were suboptimal for nonmodified Mitomycin C treated tumor. Both theoretical and practical implications of these results are discussed.
Insights
Trinitrophenyl modification of tumor cells enhances antitumor immune responses in mice, leading to increased tumor rejection and cytotoxic activity. This suggests a potential strategy for improving cancer immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor cells can be modified to enhance their immunogenicity.
- Trinitrophenyl modification is one such strategy explored to stimulate antitumor responses.
- Understanding how modified tumor cells interact with the immune system is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the efficacy of trinitrophenyl modification in stimulating syngeneic antitumor immune responses across different tumor-host systems.
- To evaluate the induction of cytotoxic antibodies and cell-mediated cytotoxicity following immunization with modified tumor cells.
- To assess the potential of trinitrophenylated tumor cells as a vaccine strategy.
Main Methods:
- Inactivation and trinitrophenyl modification of syngeneic tumor cells (YAC, G-35, LSTRA, EL-4).
- Immunization of mice (A/J, BALB/c, C57B1) with modified or unmodified tumor cells.
- Assessment of cytotoxic antibody production.
- Evaluation of tumor cell rejection frequency.
- In vitro assays for mixed leukocyte tumor interaction and cell-mediated cytotoxicity.
Main Results:
- Trinitrophenylated YAC tumor cells induced cytotoxic antibodies and enhanced tumor rejection in A/J mice.
- In BALB/c mice, trinitrophenylated G-35 and LSTRA cells showed comparable immunogenicity to non-modified cells, with some mice achieving long-term survival.
- Spleen cells from mice immunized with modified G-35 cells exhibited enhanced in vitro cytotoxic activity against G-35 tumors.
- In vitro sensitization with trinitrophenylated EL-4 cells generated a stronger cytotoxic response compared to non-modified cells, especially under suboptimal conditions.
Conclusions:
- Trinitrophenyl modification can enhance the immunogenicity of tumor cells, leading to improved antitumor immune responses.
- The effectiveness of trinitrophenyl modification varies depending on the tumor-host system.
- This modification shows promise for developing more effective cancer immunotherapy strategies.